Li Jibiao, Wang Yifeng, Matye David J, Chavan Hemantkumar, Krishnamurthy Partha, Li Feng, Li Tiangang
From the Department of Pharmacology, Toxicology and Therapeutics, Kansas University Medical Center, Kansas City, Kansas 66160 and.
the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030.
J Biol Chem. 2017 Jan 6;292(1):146-160. doi: 10.1074/jbc.M116.762005. Epub 2016 Nov 23.
The liver plays a key role in cholesterol metabolism. Impaired hepatic cholesterol homeostasis causes intracellular free cholesterol accumulation and hepatocyte injury. Sortilin 1 (SORT1) is a lysosomal trafficking receptor that was identified by genome-wide association studies (GWAS) as a novel regulator of cholesterol metabolism in humans. Here we report that SORT1 deficiency protected against cholesterol accumulation-induced liver injury and inflammation in mice. Using an LC-MS/MS-based proteomics approach, we identified liver carboxylesterase 1 (CES1) as a novel SORT1-interacting protein. Mechanistic studies further showed that SORT1 may regulate CES1 lysosomal targeting and degradation and that SORT1 deficiency resulted in higher liver CES1 protein abundance. Previous studies have established an important role of hepatic CES1 in promoting intracellular cholesterol mobilization, cholesterol efflux, and bile acid synthesis. Consistently, high cholesterol atherogenic diet-challenged Sort1 knock-out mice showed less hepatic free cholesterol accumulation, increased bile acid synthesis, decreased biliary cholesterol secretion, and the absence of gallstone formation. SORT1 deficiency did not alter hepatic ceramide and fatty acid metabolism in high cholesterol atherogenic diet-fed mice. Finally, knockdown of liver CES1 in mice markedly increased the susceptibility to high cholesterol diet-induced liver injury and abolished the protective effect against cholesterol lipotoxicity in Sort1 knock-out mice. In summary, this study identified a novel SORT1-CES1 axis that regulates cholesterol-induced liver injury, which provides novel insights that improve our current understanding of the molecular links between SORT1 and cholesterol metabolism. This study further suggests that therapeutic inhibition of SORT1 may be beneficial in improving hepatic cholesterol homeostasis in metabolic and inflammatory liver diseases.
肝脏在胆固醇代谢中起关键作用。肝脏胆固醇稳态受损会导致细胞内游离胆固醇积累和肝细胞损伤。Sortilin 1(SORT1)是一种溶酶体运输受体,通过全基因组关联研究(GWAS)被鉴定为人类胆固醇代谢的新型调节因子。在此我们报告,SORT1缺陷可保护小鼠免受胆固醇积累诱导的肝损伤和炎症。使用基于液相色谱-串联质谱(LC-MS/MS)的蛋白质组学方法,我们鉴定出肝脏羧酸酯酶1(CES1)是一种新型的与SORT1相互作用的蛋白质。机制研究进一步表明,SORT1可能调节CES1的溶酶体靶向和降解,并且SORT1缺陷导致肝脏CES1蛋白丰度升高。先前的研究已证实肝脏CES1在促进细胞内胆固醇转运、胆固醇流出和胆汁酸合成中起重要作用。同样,用高胆固醇致动脉粥样化饮食喂养的Sort1基因敲除小鼠显示肝脏游离胆固醇积累减少、胆汁酸合成增加、胆汁胆固醇分泌减少且未形成胆结石。在高胆固醇致动脉粥样化饮食喂养的小鼠中,SORT1缺陷并未改变肝脏神经酰胺和脂肪酸代谢。最后,在小鼠中敲低肝脏CES1显著增加了对高胆固醇饮食诱导的肝损伤的易感性,并消除了Sort1基因敲除小鼠对胆固醇脂毒性的保护作用。总之,本研究鉴定出了一条调节胆固醇诱导的肝损伤的新型SORT1-CES1轴,这为增进我们目前对SORT1与胆固醇代谢之间分子联系的理解提供了新见解。本研究进一步表明,对SORT1的治疗性抑制可能有益于改善代谢性和炎性肝病中的肝脏胆固醇稳态。